Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways.

Cheng J, Fan YH, Xu X, Zhang H, Dou J, Tang Y, Zhong X, Rojas Y, Yu Y, Zhao Y, Vasudevan SA, Zhang H, Nuchtern JG, Kim ES, Chen X, Lu F, Yang J.

Cell Death Dis. 2014 Feb 20;5:e1079. doi: 10.1038/cddis.2014.54.

2.

USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.

Fan YH, Cheng J, Vasudevan SA, Dou J, Zhang H, Patel RH, Ma IT, Rojas Y, Zhao Y, Yu Y, Zhang H, Shohet JM, Nuchtern JG, Kim ES, Yang J.

Cell Death Dis. 2013 Oct 17;4:e867. doi: 10.1038/cddis.2013.400.

3.

NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.

Shi Y, Ma IT, Patel RH, Shang X, Chen Z, Zhao Y, Cheng J, Fan Y, Rojas Y, Barbieri E, Chen Z, Yu Y, Jin J, Kim ES, Shohet JM, Vasudevan SA, Yang J.

Cell Death Dis. 2015 Aug 6;6:e1841. doi: 10.1038/cddis.2015.207.

4.

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J Jr, Cuvelier CA, Marine JC, De Paepe A, Bracke M, Speleman F, Vandesompele J.

J Natl Cancer Inst. 2009 Nov 18;101(22):1562-74. doi: 10.1093/jnci/djp355. Epub 2009 Nov 10.

PMID:
19903807
5.

Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.

Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL.

Br J Pharmacol. 2008 Feb;153(4):657-68. Epub 2007 Dec 3.

6.

Oral RKS262 reduces tumor burden in a neuroblastoma xenograft animal model and mediates cytotoxicity through SAPK/JNK and ROS activation in vitro.

Singh RK, Dorf L, DeMartino A, Illenye S, Koto K, Currier EA, Ashikaga T, Kim KK, Brard L, Sholler GL.

Cancer Biol Ther. 2011 Jun 15;11(12):1036-45. Epub 2011 Jun 15.

PMID:
21532338
7.

New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.

Di Paolo D, Yang D, Pastorino F, Emionite L, Cilli M, Daga A, Destafanis E, Di Fiore A, Piaggio F, Brignole C, Xu X, Liang C, Gibbons J, Ponzoni M, Perri P.

Oncotarget. 2015 Oct 6;6(30):28774-89. doi: 10.18632/oncotarget.4342.

8.

The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.

Peirce SK, Findley HW, Prince C, Dasgupta A, Cooper T, Durden DL.

Cancer Chemother Pharmacol. 2011 Aug;68(2):325-35. doi: 10.1007/s00280-010-1486-7. Epub 2010 Oct 24.

9.

Mechanisms of neuroblastoma cell growth inhibition by CARP-1 functional mimetics.

Muthu M, Cheriyan VT, Munie S, Levi E, Frank J, Ashour AE, Singh M, Rishi AK.

PLoS One. 2014 Jul 17;9(7):e102567. doi: 10.1371/journal.pone.0102567. eCollection 2014.

10.

The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.

Luo P, Lin M, Li L, Yang B, He Q.

PLoS One. 2011;6(11):e27298. doi: 10.1371/journal.pone.0027298. Epub 2011 Nov 7.

11.

Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.

Burmakin M, Shi Y, Hedström E, Kogner P, Selivanova G.

Clin Cancer Res. 2013 Sep 15;19(18):5092-103. doi: 10.1158/1078-0432.CCR-12-2211. Epub 2013 Jul 17.

12.

Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma.

Raguénez G, Mühlethaler-Mottet A, Meier R, Duros C, Bénard J, Gross N.

BMC Cancer. 2009 Mar 30;9:97. doi: 10.1186/1471-2407-9-97.

13.

Juglanin induces apoptosis and autophagy in human breast cancer progression via ROS/JNK promotion.

Sun ZL, Dong JL, Wu J.

Biomed Pharmacother. 2017 Jan;85:303-312. doi: 10.1016/j.biopha.2016.11.030. Epub 2016 Nov 26.

PMID:
27899257
14.

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.

Wang Y, Wang L, Guan S, Cao W, Wang H, Chen Z, Zhao Y, Yu Y, Zhang H, Pang JC, Huang SL, Akiyama Y, Yang Y, Sun W, Xu X, Shi Y, Zhang H, Kim ES, Muscal JA, Lu F, Yang J.

Sci Rep. 2016 Jan 20;6:19423. doi: 10.1038/srep19423.

15.

Chaetocin-induced ROS-mediated apoptosis involves ATM-YAP1 axis and JNK-dependent inhibition of glucose metabolism.

Dixit D, Ghildiyal R, Anto NP, Sen E.

Cell Death Dis. 2014 May 8;5:e1212. doi: 10.1038/cddis.2014.179.

16.
17.

TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Croucher JL, Iyer R, Li N, Molteni V, Loren J, Gordon WP, Tuntland T, Liu B, Brodeur GM.

Cancer Chemother Pharmacol. 2015 Jan;75(1):131-41. doi: 10.1007/s00280-014-2627-1. Epub 2014 Nov 14.

18.

Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.

Iyer R, Wehrmann L, Golden RL, Naraparaju K, Croucher JL, MacFarland SP, Guan P, Kolla V, Wei G, Cam N, Li G, Hornby Z, Brodeur GM.

Cancer Lett. 2016 Mar 28;372(2):179-86. doi: 10.1016/j.canlet.2016.01.018. Epub 2016 Jan 18.

19.

Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma.

Becker K, Marchenko ND, Maurice M, Moll UM.

Cell Death Differ. 2007 Jul;14(7):1350-60. Epub 2007 Mar 23.

20.

Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53.

Karlsson J, Øra I, Pörn-Ares I, Påhlman S.

Clin Cancer Res. 2004 May 1;10(9):3179-88.

Supplemental Content

Support Center